Loading…
XCUR
Exicure Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 30205M309
$1.29-8.51%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $8.44M
- P/E
- —
- Forward P/E
- —
- P/B
- 3.9x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.31
- ROE
- -168.37%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 3.66
- 52-week high
- $9.48
- 52-week low
- $1.05
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.3% over 5Y.
today you would have $6.78▼ -99.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 8 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $5.42 | $13.67 | $2.90 | $5.75 | $30.30 | $265.50 | $429.00 | $531.00 | |
| P/S | 172.7x | — | 172.7x | — | 0.3x | — | 9.4x | 192.3x | 1330.7x |
| P/B | 2.8x | 8.8x | 12.8x | 1.8x | 0.6x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CODXCo-Diagnostics, Inc. | $1.21 | — | 0.5x | — | -174.77% | $8.45M |
| MGRXMangoceuticals Inc | $0.40 | — | 0.6x | — | -95.10% | $8.67M |
| XWELXWELL, Inc. | $1.01 | — | 20.6x | — | -361.36% | $8.68M |
| EVGNEvogene Ltd. | $0.55 |
About the company
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
- 1
- Redwood City, United States
Company description provided by Yahoo Finance.